New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

被引：242
作者：
Isler, Burcu [1 ]
Doi, Yohei [2 ]
Bonomo, Robert A. [3 ,4 ]
Paterson, David L. [5 ]
机构：
[1] Istanbul Educ & Res Hosp, Istanbul, Turkey
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[3] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Cleveland, OH USA
[4] Case Western Reserve Univ, Vet Affairs Ctr Antimicrobial Resistance & Epidem, Cleveland, OH 44106 USA
[5] Univ Queensland, Ctr Clin Res, Royal Brisbane & Womens Hosp Campus, Brisbane, Qld, Australia
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 01期
关键词：
Acinetobacter; cefiderocol; GRAM-NEGATIVE BACTERIA; IN-VITRO ACTIVITY; SIDEROPHORE CEPHALOSPORIN; ANTIMICROBIAL THERAPY; MULTIDRUG; COLISTIN; ERAVACYCLINE; ENTEROBACTERIACEAE; FLUOROCYCLINE; COMBINATION;
D O I：
10.1128/AAC.01110-18
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.
引用
收藏
页数：17
相关论文
共 129 条
[1]   Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City [J].
Abdallah, Marie ;
Olafisoye, Olawole ;
Cortes, Christopher ;
Urban, Carl ;
Landman, David ;
Quale, John .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (03) :1802-1805
[2]  
Abedon Stephen T, 2011, Bacteriophage, V1, P66
[3]  
AiCuris Pharmaceuticals, 2017, AIC IN CLIN DEV AIC4
[4]  
Aleshkin A V, 2016, Bacteriophage, V6, pe1251379, DOI 10.1080/21597081.2016.1251379
[5]  
[Anonymous], ACTIVITY NEW CARBAPE
[6]  
[Anonymous], 27 EUR C CLIN MICR I
[7]  
[Anonymous], 2017, OPEN FORUM INFECT DI
[8]  
Aridis Pharmaceuticals, 2018, AR 401 FULL HUM MON
[9]   Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia [J].
Aydemir, H. ;
Akduman, D. ;
Piskin, N. ;
Comert, F. ;
Horuz, E. ;
Terzi, A. ;
Kokturk, F. ;
Ornek, T. ;
Celebi, G. .
EPIDEMIOLOGY AND INFECTION, 2013, 141 (06) :1214-1222
[10]  
Barnes MD, 2017, NOVEL SS LACTAMASE I
12345678910